Race Oncology Lung Cancer Trial Update: ASX 200 Spotlight

Highlights:

• Ethics approval secured for HARNESS-1 trial.

• Multi-centre study to investigate RC220 combination.

• ctDNA used for patient enrolment in NSCLC trial.

Race Oncology (ASX:RAC) begins HARNESS-1 lung cancer trial, exploring RC220 and osimertinib in EGFR-mutated NSCLC with ctDNA patient screening.

Race Oncology Advances Lung Cancer Research Race Oncology Ltd (ASX:RAC) has recently received human ethics approval to commence the HARNESS-1 Phase 1a/b lung cancer trial. This trial is designed to assess the safety, tolerability, and pharmacokinetics of RC220 in combination with osimertinib for adults with non-small cell lung cancer (NSCLC) harbouring activating epidermal growth factor receptor mutations. The approval highlights the significant strides Race Oncology is making in innovative cancer treatment research within the ASX 200 landscape.

What is the HARNESS-1 Trial? The HARNESS-1 trial represents a pivotal Phase 1a/b clinical study aimed at addressing the unmet medical need in NSCLC patients. The study combines RC220 (E,E-bisantrene, RCDS1) with osimertinib to explore potential therapeutic benefits and monitor patient response using cutting-edge circulating tumour DNA (ctDNA) screening methods. This multi-centre trial includes Monash Health in Clayton, Victoria, as the lead site for patient enrolment.

How Will Patients Be Enrolled? Patients with EGFR-mutated NSCLC currently on standard-of-care osimertinib will be screened using ctDNA technology. The trial initiates with a ctDNA screening stage, followed by dose escalation of RC220. Patients will receive intravenous RC220 on a specified schedule in combination with osimertinib. Treatment continues until disease control, completion of treatment duration, disease progression, unacceptable toxicity, or patient withdrawal.

What Are the Study Phases?

• Phase 1a: Focuses on safety, tolerability, and determining the maximum tolerated dose of RC220 through a Bayesian dose-escalation design.

• Phase 1b: Following dose establishment, this randomised, double-blind stage evaluates secondary and exploratory endpoints, including progression-free survival, overall survival, ctDNA changes, and cancer-specific mutations.

Which Companies Are Involved? Apart from Race Oncology (ASX:RAC), the trial incorporates collaboration with Beyond Drug Development and clinical oversight at Monash Health. These entities support the research framework and ensure rigorous adherence to clinical standards.

How Does RC220 Work? RC220 is a novel therapeutic agent aimed at enhancing NSCLC treatment efficacy when combined with osimertinib. Its mechanism focuses on addressing resistance in third-generation EGFR-mutated NSCLC, providing a complementary approach to existing treatments.

What Are the Trial Objectives? The study aims to evaluate several outcomes: safety profile, pharmacokinetics, patient tolerability, and potential efficacy in controlling disease progression. Insights from the trial may inform future development strategies for RC220 in NSCLC.

How Will Data Be Collected? Patient responses, adverse events, and pharmacokinetic parameters are closely monitored throughout the study. The double-blind Phase 1b stage further enhances data reliability and ensures objective evaluation of treatment outcomes.

What Are the Research Implications? The HARNESS-1 trial underscores the ongoing evolution of lung cancer therapies and highlights the role of precision medicine. Using ctDNA screening enables tailored treatment pathways for patients with specific genetic profiles.

ASX Market Context Race Oncology (ASX:RAC) operates within the broader ASX stock market environment, demonstrating the integration of clinical innovation with publicly listed healthcare companies. Investors and stakeholders in the ASX 100 and ASX ordinaries stocks can observe developments in biotechnology alongside established sectors such as ASX mining stocks and ASX dividend stocks.

How Will This Affect NSCLC Treatment Landscape? By targeting patients with EGFR-mutated NSCLC, the trial seeks to fill therapeutic gaps left by existing tyrosine kinase inhibitors. The combination of RC220 and osimertinib introduces an innovative treatment approach that may influence future clinical guidelines.

Which Sites Will Participate? The HARNESS-1 trial will expand across multiple clinical sites, enhancing the geographic diversity of patient enrolment. Monash Health serves as the primary site, with additional centres to follow, allowing broader data collection and improved study validity.

What Are the Expected Outcomes? While patient-specific outcomes vary, the trial focuses on generating comprehensive safety and pharmacokinetic data. Secondary endpoints such as ctDNA changes and progression-free survival offer insights into RC220’s therapeutic potential.

How Is Patient Safety Ensured? Safety protocols are a core component of HARNESS-1. Monitoring includes adverse event tracking, dose adjustments, and patient withdrawal options. The design prioritises patient well-being while enabling effective data collection.

What Is the Role of ctDNA? Circulating tumour DNA allows precise identification of patients eligible for the trial. This non-invasive method enhances treatment targeting and may inform future biomarker-driven therapy development in NSCLC.

What Are the Study Timelines? The trial has secured ethics approval, and patient enrolment is anticipated to begin shortly, followed by dose escalation and double-blind stages. Multi-centre expansion is planned in subsequent months to maximise participant representation.

Why Is This Trial Significant? HARNESS-1 represents a key step in advancing cancer research in Australia. The integration of novel therapeutics like RC220 into clinical practice could redefine treatment protocols for NSCLC, benefiting patient outcomes.

Race Oncology Ltd (ASX:RAC) continues to push boundaries in oncology research through the HARNESS-1 trial. By combining RC220 with osimertinib, the study highlights innovative approaches in NSCLC treatment while operating within the ASX 200 framework, reflecting a blend of clinical excellence and market relevance.